2009-11-02 23:08:04 -

MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences.

- Imperial Capital’s 3 rd Annual Global Opportunities Conference on Thursday, November 5, 2009 at 2:10 PM (EST) at the New York Palace Hotel in New York, New York
- Lazard Capital Market’s 6 th Annual Healthcare Conference on Tuesday, November 17, 2009 at 2:10 PM (EST) at the St. Regis Hotel in New York, New York


Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at www.mannkindcorp.com : .

Replays of the presentations will be available for 14 days.



About MannKind Corporation

MannKind Corporation

(Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFRESA®, MKC253, MKC1106-PP, and MKC1106-MT. MannKind has submitted an NDA to the FDA requesting approval of AFRESA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Its other programs are currently in Phase 1 clinical trials. MannKind maintains a website at www.mannkindcorp.com : to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.


MannKind CorporationMatthew J. PfefferCorporate Vice

President and Chief Financial Officer661-775-5300 mpfeffer@mannkindcorp.com : mailto:mpfeffer@mannkindcorp.com